Drug delivery devices and endoscopy components

Abstract

The present invention discloses a drug delivery device and an endoscopic assembly, relating to the technical field of endoscopes. The drug delivery device includes a first tube body, a balloon, and a light-emitting structure. By setting the balloon as a light-transmitting and inflatable structure, and making the structural layer of the balloon enclose an inner cavity, the inner cavity is hermetically arranged and communicated with the distal end of the first tube body. At the same time, the first tube body is inserted into the inner cavity, and then a light-emitting structure is arranged in the balloon. The light emitted by the light-emitting structure and the photosensitive crosslinking drug composite layer located outside the structural layer are used to induce a crosslinking reaction. When the balloon is inserted into the uterus, liquid can be injected into the balloon through the first tube body to make the balloon expand. After the balloon expands, it can abut against the endometrium. After the light-emitting structure emits light, the photosensitive crosslinking drug composite layer can adhere to the surface of the endometrium, and then the drug located in the photosensitive crosslinking drug composite layer can fully and tightly adhere to the endometrium to continuously treat or repair the membrane layer of the endometrium.

Description

Technical Field

[0001] The present invention relates to the field of endoscopes, and particularly to a drug delivery device and an endoscopic assembly. Background Art

[0002] The uterine packing balloon is a medical device mainly for treating gynecological diseases such as uterine bleeding in women. It can be used to place the balloon inside the uterus and expand the balloon to achieve the effect of expanding and compressing to stop bleeding, and can also be used to deliver drugs through the balloon to the uterus for treating the endometrium or repairing the membrane layer.

[0003] However, due to the insufficient wall thickness of the germinal layer when the endometrium is damaged, it is difficult for the uterine packing balloon in the prior art to attach drugs to the endometrium for continuous treatment of the endometrium or repair of the membrane layer. Summary of the Invention

[0004] The present invention discloses a drug delivery device and an endoscopic assembly to at least partially improve the above technical problems.

[0005] To solve the above problems, the present invention adopts the following technical solutions:

[0006] On the one hand, an embodiment of the present application provides a drug delivery device, including: a first tube body, a balloon, and a light-emitting structure. The balloon is a light-transmitting structure and can be inflated. The balloon has a structural layer and a photosensitive crosslinking drug composite layer. The structural layer encloses an inner cavity, and the inner cavity is hermetically arranged at the distal end of the first tube body and communicated with the first tube body. The first tube body extends into the inner cavity. The light-emitting structure is located inside the balloon, and the light emitted by the light-emitting structure can induce a crosslinking reaction with the photosensitive crosslinking drug composite layer.

[0007] In one embodiment, the structural layer includes a first structural part and a second structural part stacked along the radial direction of the balloon. The first structural part is connected to the second structural part and is close to the inner cavity. The photosensitive crosslinking drug composite layer is arranged on the second structural part, and the first structural part is arranged to expand to the same surface as the second structural part when the balloon is inflated.

[0008] In one embodiment, the photosensitive crosslinking drug composite layer is arranged on a partial area of the second structural part, and there is a first gap between adjacent photosensitive crosslinking drug composite layers.

[0009] In one embodiment, the photosensitive crosslinking drug composite layer includes: a photosensitive crosslinking agent, a porous carrier, and a drug. The porous carrier is connected to the second structural part, the photosensitive crosslinking agent is arranged on the peripheral side wall of the porous carrier, and the drug is arranged on the porous carrier.

[0010] In one embodiment, there is a second gap between adjacent first structural portions, and the second gap points to the center of the first structural portion connected between two adjacent first structural portions.

[0011] In one embodiment, the distal end of the first tube body has a necked-down region, the radial dimension of the necked-down region is smaller than the radial dimension of the proximal end of the first tube body, and the structural layer is hermetically connected to the necked-down region.

[0012] In one embodiment, the region where the first tube body extends into the interior of the balloon serves as the light-emitting structure.

[0013] In one embodiment, the drug delivery device further includes: a second tube body disposed inside the first tube body, the first tube body being a light-transmitting structure, and the second tube body serving as the light-emitting structure.

[0014] In one embodiment, the drug delivery device further includes: a second tube body disposed inside the first tube body and communicating with the interior of the first tube body, both the first tube body and the second tube body being light-transmitting structures, and the light-emitting structure being detachably disposed inside the second tube body.

[0015] On the other hand, an endoscopic assembly is further provided in an embodiment of the present application, including an endoscope and the drug delivery device as described above, the endoscope having an instrument channel, and the drug delivery device being detachably disposed inside the instrument channel.

[0016] The technical solution adopted by the present invention can achieve the following beneficial effects:

[0017] The drug delivery device provided in the embodiment of the present application, by setting the balloon as a light-transmitting and inflatable structure, and enabling the structural layer of the balloon to enclose an inner cavity, hermetically setting and communicating the inner cavity with the distal end of the first tube body, while extending the first tube body into the inner cavity, and then arranging a light-emitting structure inside the balloon, using the light emitted by the light-emitting structure to induce a crosslinking reaction with the photosensitive crosslinking drug composite layer located outside the structural layer. When the balloon is inserted into the uterus, liquid can be injected into the balloon through the first tube body to make the balloon expand. After the balloon expands, it can abut against the endometrium. After the light-emitting structure emits light, the photosensitive crosslinking drug composite layer can adhere to the surface of the endometrium, and further enable the drug located in the photosensitive crosslinking drug composite layer to fully and tightly adhere to the endometrium, so as to continuously treat or repair the membrane layer of the endometrium. Applying the above drug delivery device to the endoscopic assembly can also solve the above technical problems. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required for the description of the embodiments or the prior art. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0019] Figure 1 FIG. 4 shows a schematic structural diagram of a balloon in a contracted state in an endoscopic assembly according to an embodiment of the present application;

[0020] Figure 2 FIG. 8 shows a schematic structural diagram of a balloon in an inflated state in an endoscopic assembly according to an embodiment of the present application;

[0021] Figure 3 FIG. 12 shows a schematic structural diagram of a balloon in a contracted state after an endoscopic assembly extends into the uterus according to an embodiment of the present application;

[0022] Figure 4 FIG. 16 shows a schematic structural diagram of a balloon in an inflated state after an endoscopic assembly extends into the uterus according to an embodiment of the present application;

[0023] Figure 5 is Figure 1 an enlarged view of part A in FIG.

[0024] Figure 6 is Figure 2 an enlarged view of part B in FIG.

[0025] Figure 7 FIG. 32 shows a cross-sectional view of a partial structure of an endoscopic assembly according to an embodiment of the present application;

[0026] Figure 8 FIG. 36 shows a schematic partial structural diagram of a balloon in a contracted state in a drug delivery device according to an embodiment of the present application;

[0027] Figure 9 FIG. 40 shows a schematic structural diagram of a balloon in an inflated state and in contact with the endometrium in a drug delivery device according to an embodiment of the present application.

[0028] In the figure: 1. Endoscopic assembly; 10. Drug delivery device; 110. First tube body; 111. Narrowing area; 120. Balloon; 121. Structural layer; 1211. First structural part; 1212. Second structural part; 1213. First gap; 1214. Second gap; 122. Photosensitive cross-linked drug composite layer; 1221. Photosensitive cross-linking agent; 1222. Porous carrier; 123. Inner cavity; 130. Light-emitting structure; 140. Second tube body; 20. Endoscope; 210. Instrument channel; 220. Liquid injection channel; 2. Uterus. Detailed Implementation Modes

[0029] To make the objectives, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be described in detail below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of them. All other implementation modes obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts fall within the scope protected by the present invention.

[0030] The terms "first", "second", etc. in the description and claims of this application are used to distinguish similar objects, rather than to describe a specific order or sequence. It should be understood that such used data can be interchanged under appropriate circumstances so that the embodiments of this application can be implemented in an order other than those illustrated or described here, and the objects distinguished by "first", "second", etc. are usually of the same type, and do not limit the number of objects. For example, the first object can be one or multiple. In addition, "and / or" in the description and claims means at least one of the connected objects. The character " / ", generally represents an "or" relationship between the associated objects before and after.

[0031] In the embodiments of this application, "proximal end" and "distal end" refer to the relative distances of each component from the user in the usage environment. Among them, the end closer to the user is designated as the "proximal end", and the end farther from the user is designated as the "distal end".

[0032] The inventive concept of this application is described here:

[0033] The uterine packing balloon is a medical device mainly for gynecological diseases such as uterine bleeding in women. It can be used to place the balloon inside the uterus and expand the balloon to achieve the effect of expanding and compressing to stop bleeding, and can also be used to deliver drugs through the balloon to the uterus for treating or repairing the endometrial layer.

[0034] However, due to the insufficient thickness of the germinal layer wall when the endometrium is damaged, it is difficult for the uterine packing balloon in the prior art to attach drugs to the endometrium for continuous treatment or repair of the endometrial layer. If the method of injecting drugs at a fixed point is adopted, although this can ensure that the drugs can fully contact the endometrium, this method not only has a small action range, but also is very complicated in operation.

[0035] Based on this, the inventor provides a drug delivery device and an endoscopic assembly. The drug delivery device can use the photocrosslinking reaction to tightly bond the carrier with drugs to the endometrium, so as to achieve large-area drug application to the endometrium and is simple in operation.

[0036] The following combines the attached Figures 1 to 9, a detailed description of an endoscopic assembly 1 and an endoscope 20 provided by the present application is given through specific embodiments and their application scenarios.

[0037] Please refer to Figures 1 - 4 simultaneously. An endoscopic assembly 1 is provided in an embodiment of the present application. The endoscopic assembly 1 can be used for applying medicine to the endometrium to continuously treat or repair the endometrium. The endoscopic assembly 1 may include: an endoscope 20 and a drug delivery device 10. Among them, the endoscope 20 can be used as a carrier of the drug delivery device 10. The drug delivery device 10 is sent into the uterus 2 through the endoscope 20, and the drug delivery device 10 is used to attach the drug to the endometrium.

[0038] Please refer to Figure 5 and Figure 6 simultaneously. The endoscope 20 may have an instrument channel 210 and a liquid injection channel 220. The instrument channel 210 can be used to accommodate the drug delivery device 10, and the liquid injection channel 220 can communicate with the drug delivery device 10. In this embodiment, the drug delivery device 10 is detachably disposed in the instrument channel 210 so that the endoscope 20 can be reused.

[0039] Please refer to Figure 5 and Figure 7 simultaneously. The drug delivery device 10 may include: a first tube body 110, a balloon 120, and a light emitting structure 130. The balloon 120 can be connected to the first tube body 110. The light emitting structure 130 can be used to emit light and trigger a crosslinking reaction induced by a photosensitive crosslinking agent 1221 in the balloon 120, so that the balloon 120 can have an adhesive property. Furthermore, when the balloon 120 contacts the endometrium, the drug can be adhered to the endometrium.

[0040] Specifically, the first tube body 110 can communicate with the liquid injection channel 220. The first tube body 110 can be used to inject liquid into the balloon 120 to make the balloon 120 expand. The present application embodiment does not limit the aforementioned liquid. For example, in some embodiments, it can be physiological saline, etc. The balloon 120 can be connected to the distal end of the first tube body 110 and is hermetically arranged with the distal end of the first tube body 110. In this embodiment, the balloon 120 can be set as a light-transmitting and expandable structure.

[0041] In one embodiment, the distal end of the first tube body 110 may have a constricted area 111. The radial dimension of the constricted area 111 may be smaller than the radial dimension of the proximal end of the first tube body 110. The balloon 120 can be connected to the constricted area 111. This can make the dimensions of each part of the entire drug delivery device 10 tend to be consistent, and avoid the distal end of the drug delivery device 10 becoming larger in size due to the connection of the balloon 120, resulting in difficulty in smoothly moving in the instrument channel 210.

[0042] Please refer to Figure 8 and Figure 9 simultaneously. The balloon 120 may have a structural layer 121 and a photo-crosslinkable drug composite layer 122. The structural layer 121 may enclose an inner cavity 123. The first tube body 110 may extend into the inner cavity 123. It can be understood that since the balloon 120 has a relatively low structural strength and is prone to collapse when in a contracted state, extending the first tube body 110 into the inner cavity 123 can make the first tube body 110 serve as a support structure for the balloon 120, which can facilitate the delivery of the drug delivery device 10 into the uterus 2. At the same time, during the process of delivering the drug delivery device 10 into the uterus 2, the first tube body 110 can also play a guiding role.

[0043] In a specific embodiment, the photo-crosslinkable drug composite layer 122 may include: a photo-crosslinking agent 1221, a porous carrier 1222, and a drug. The porous carrier 1222 can be used to carry the drug. The specific form of the porous carrier 1222 is not limited in the embodiments of the present application. For example, in one embodiment, the porous carrier 1222 may adopt an inorganic carrier, such as silica, aluminum hydroxide, etc. In another embodiment, the porous carrier 1222 may also be an organic carrier, such as polyester, polyamide, polyorthoester, polyethylene oxide, polyamide ester, etc., which can be specifically set according to the actual situation. The photo-crosslinking agent 1221 may be disposed on the peripheral sidewall of the porous carrier 1222. The photo-crosslinking agent 1221 can be used to cooperate with the light emitted by the light-emitting structure 130 and induce a crosslinking reaction, so that the porous carrier 1222 can adhere to the endometrium, and then the drug can be in full contact with the endometrium. The specific form of the drug is also not limited in the embodiments of the present application. For example, it may be platelet-rich plasma (PRP).

[0044] For details, please refer to Figure 8 simultaneously. The structural layer 121 may include a first structural portion 1211 and a second structural portion 1212 that are stacked along the radial direction of the balloon 120. The first structural portion 1211 may be connected to the second structural portion 1212, and the first structural portion 1211 is closer to the inner cavity 123 than the second structural portion 1212. The photo-crosslinkable drug composite layer 122 may be disposed on the second structural portion 1212. That is to say, in this embodiment, the photo-crosslinkable drug composite layer 122 may be located on the outer surface of the balloon 120, and the structural layer 121 may be located on the inner surface of the balloon 120. Among them, the first structural portion 1211 may be configured to expand and unfold to be on the same surface as the second structural portion 1212.

[0045] Further, in one embodiment, the photosensitive crosslinking drug composite layer 122 is disposed in a partial area on the second structural part 1212. Specifically, the porous carrier 1222 can be disposed in a partial area on the second structural part 1212, and a first gap 1213 is provided between adjacent photosensitive crosslinking drug composite layers 122. It can be understood that, since the photosensitive crosslinking drug composite layer 122 usually has the property of being light-impermeable, providing the first gap 1213 between adjacent photosensitive crosslinking drug composite layers 122 can facilitate the light emitted by the light-emitting structure 130 to induce a crosslinking reaction with the photosensitive crosslinking agent 1221 in the photosensitive crosslinking drug composite layer 122.

[0046] In one embodiment, a second gap 1214 can be provided between adjacent first structural parts 1211, and the second gap 1214 points to the center of the first structural part 1211 connected between the two adjacent first structural parts 1211. That is to say, in this embodiment, when the first structural part 1211 is unfolded, the second structural part 1212 can be made to be stressed more evenly, avoiding partial collapse of the second structural part 1212 during the unfolding of the first structural part 1211, and further avoiding loosening and falling off of the porous carrier 1222 located on the second structural part 1212.

[0047] The embodiments of the present application do not limit the specific position and form of the light-emitting structure 130. For example, in one embodiment, the area where the first tube body 110 extends into the interior of the balloon 120 can be used as the light-emitting structure 130. In a preferred embodiment, the first tube body 110 can also be provided as a light-transmitting structure, which can further facilitate the crosslinking reaction of the photosensitive crosslinking agent 1221.

[0048] In addition, in another embodiment, the drug delivery device 10 can further include a second tube body 140. The second tube body 140 can be disposed inside the first tube body 110. The second tube body 140 can be used as the light-emitting structure 130, and in this embodiment, the first tube body 110 is also a light-transmitting structure. It can be understood that the embodiments of the present application do not limit the connection manner between the second tube body 140 and the first tube body 110. For example, it can be integrally formed, or it can be slidably disposed and detachably connected, etc., and can be specifically set according to the actual situation.

[0049] For another example, in yet another embodiment, the drug delivery device 10 may also include a second tube body 140, which may also be disposed inside the first tube body 110. However, in this embodiment, the second tube body 140 is only used as a conduit, and the light-emitting structure 130 is detachably disposed inside the second tube body 140. It can be understood that since the first tube body 110 is required to inject liquid into the inner cavity 123 of the balloon 120, disposing the light-emitting structure 130 separately inside the second tube body 140 can avoid the influence of the liquid on the light-emitting structure 130.

[0050] In some other embodiments, the light-emitting structure 130 may also be disposed between the structural layer 121 and the photosensitive crosslinking drug composite layer 122, which can make the distance between the light-emitting structure 130 and the photosensitive crosslinking agent 1221 closer, thereby improving the efficiency of the crosslinking reaction of the photosensitive crosslinking agent 1221. Specifically, the location where the light-emitting structure 130 is disposed can be set according to the actual situation.

[0051] The drug delivery device 10 provided by the embodiments of the present application, by setting the balloon 120 as a light-transmitting and expandable structure, and making the structural layer 121 of the balloon 120 enclose the inner cavity 123, sealing and connecting the inner cavity 123 with the distal end of the first tube body 110, while extending the first tube body 110 into the inner cavity 123, and then disposing the light-emitting structure 130 inside the balloon 120, using the light emitted by the light-emitting structure 130 and the photosensitive crosslinking drug composite layer 122 located outside the structural layer 121 to induce a crosslinking reaction. When the balloon 120 is inserted into the uterus 2, liquid can be injected into the balloon 120 through the first tube body 110 to make the balloon 120 expand. After the balloon 120 expands, it can abut against the endometrium. After the light-emitting structure 130 emits light, the photosensitive crosslinking drug composite layer 122 can adhere to the surface of the endometrium, and then the drug located in the photosensitive crosslinking drug composite layer 122 can be fully and tightly attached to the endometrium to continuously treat or repair the membrane layer of the endometrium. Applying the above drug delivery device 10 to the endoscopic assembly 1 can also solve the above technical problems.

[0052] It should be noted that in this article, the terms "include", "comprise" or any other variant thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements not only includes those elements but also includes other elements not expressly listed, or also includes elements inherent to such process, method, article or device. Without further limitation, an element defined by the statement "including one..." does not exclude the existence of additional identical elements in the process, method, article or device including that element.

[0053] In addition, it should be noted that the scope of the methods and apparatuses in the embodiments of the present application is not limited to performing functions in the order shown or discussed, and may also include performing functions in a substantially simultaneous manner or in the reverse order according to the functions involved. For example, the described methods may be performed in an order different from that described, and various steps may also be added, omitted, or combined. Additionally, the features described with reference to certain examples may be combined in other examples.

[0054] As described above, the foregoing are only specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art within the technical scope disclosed by the present invention can easily conceive of changes or substitutions, which should all be covered within the protection scope of the present invention.

Claims

1. A drug release device, characterized in that: include: A first tube body, the first tube body is used to inject liquid into the balloon, so as to expand the balloon disposed at the distal end of the first tube body; A balloon, wherein the balloon is a light-transmitting structure and is expandable, and comprises a structural layer and a photosensitive cross-linked drug composite layer, wherein the photosensitive cross-linked drug composite layer is located on the outer surface of the balloon, and the structural layer is located on the inner surface of the balloon, wherein the structural layer encloses an inner cavity, wherein the inner cavity is sealed with the distal end of the first tube body and is in communication with the first tube body, and wherein the first tube body extends into the inner cavity; And a light-emitting structure, wherein the light-emitting structure is located in the balloon, and the light emitted by the light-emitting structure can induce a cross-linking reaction with the photosensitive cross-linking drug composite layer; the balloon is provided with multiple photosensitive cross-linking drug composite layers, and a first gap is set between adjacent photosensitive cross-linking drug composite layers, and the first gap is used to induce a cross-linking reaction through light.

2. The drug release device according to claim 1, characterized in that: The structural layer includes a first structural part and a second structural part stacked along the radial direction of the balloon, the first structural part is connected to the second structural part and close to the inner cavity, the photosensitive cross-linked drug composite layer is arranged on the second structural part, and the first structural part is configured to expand to the same surface as the second structural part when the balloon is inflated.

3. The drug release device according to claim 2, characterized in that: The photosensitive cross-linked drug composite layer is arranged in a partial area on the second structural part.

4. The drug release device according to claim 3, characterized in that: The photosensitive cross-linking drug composite layer includes: a photosensitive cross-linking agent, a porous carrier and a drug, the porous carrier is connected to the second structural part, the photosensitive cross-linking agent is arranged on the peripheral side wall of the porous carrier, and the drug is arranged on the porous carrier.

5. The drug release device according to claim 2, characterized in that: There is a second gap between adjacent first structure parts, and the second gap points to the center of the first structure part connecting two adjacent first structure parts.

6. The drug release device according to claim 1, characterized in that: The distal end of the first tube body has a necked area, the radial dimension of the necked area is smaller than the radial dimension of the proximal end of the first tube body, and the structural layer is sealingly connected to the necked area.

7. The drug release device according to any one of claims 1 to 5, characterized in that: The area of ​​the first tube extending into the interior of the balloon serves as the light-emitting structure.

8. The drug release device according to any one of claims 1 to 5, characterized in that: The drug release device further includes: a second tube body, which is arranged inside the first tube body, the first tube body is a light-transmitting structure, and the second tube body serves as the light-emitting structure.

9. The drug release device according to any one of claims 1 to 5, characterized in that: The drug release device also includes: a second tube body, which is arranged inside the first tube body and communicated with the inside of the first tube body. The first tube body and the second tube body are both light-transmitting structures, and the light-emitting structure is detachably arranged inside the second tube body.

10. An endoscope assembly, characterized in that: It comprises an endoscope and a drug releasing device as claimed in any one of claims 1 to 9, wherein the endoscope has an instrument channel, and the drug releasing device is detachably disposed in the instrument channel.

Images